Project Grant R01DA067138
- The National Institute on Drug Abuse awarded Boston Medical Center Corporation $296,460 under NIDA's Drug Use and Addiction Research Programs (CFDA 93.279) on September 1, 2026, for a research project examining housing stability and overdose prevention among people transitioning from shelter into housing. The award funds a prospective longitudinal cohort study following individuals as they move out of shelter into housing, with one-year follow-up tracking substance use outcomes (non-fatal...
- The National Institute on Drug Abuse awarded Boston Medical Center Corporation $231,600 on September 15, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support scholarships and speaker fees for the annual Academic Consortium of Criminal Justice Health (ACCJH) Conference. The funding supports a 2-day conference that convenes clinicians, researchers, and people with firsthand experience of incarceration to discuss emerging topics at the intersection of incarceration...
- The National Institute on Drug Abuse awarded Trustees of Boston University $193,751 on May 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support a career development research initiative examining quality of care in outpatient substance use disorder treatment facilities. The award funds a five-year training and research plan designed to develop the principal investigator as an independent substance use disorder services researcher. The research uses a novel...
- The National Institute on Drug Abuse awarded The General Hospital Corporation (Massachusetts General Hospital) $453,750 under the Drug Use and Addiction Research Programs (CFDA 93.279) on September 1, 2026. The award funds a mixed-methods examination of adolescent overdose and return to high-risk drug use after inpatient addiction treatment. The research leverages an existing longitudinal dataset of adolescents aged 12–19 followed for 12 months after treatment discharge, 52 percent of whom...
- The National Institute on Drug Abuse awarded Boston Medical Center Corporation $1,106,433 under the Drug Use and Addiction Research Programs (CFDA 93.279) on September 1, 2026, for development and evaluation of a universal overdose prevention intervention delivered in primary care settings. Boston Medical Center will develop and pilot an evidence-based intervention designed to increase youth awareness of fentanyl and emerging drugs in the drug supply, knowledge of overdose risk reduction...
- The National Institute on Drug Abuse awarded Massachusetts General Hospital $197,640 on March 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a four-year project examining the clinical impact and cost-effectiveness of integrating infectious disease care into rapid-access substance use bridge clinics. The research addresses the syndemic of substance use disorder and infections among people who inject drugs, who face elevated risk of overdose, acute bacterial...
- The National Institute on Drug Abuse awarded Boston University (Trustees of Boston University, doing business as Boston University Medical Campus) $732,747 on June 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to quantify the health effects of cannabis use and cannabis use disorder on geriatric syndromes and HIV outcomes through causal effects analysis in the Veterans Aging Cohort Study and the Mt. Sinai HIV Cohort. The project runs through March 31, 2031, with place...
- Federal Grant Award Summary Boston Medical Center Corporation received a $356,630 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded September 1, 2025, with completion scheduled for August 31, 2027. The grant supports immune profiling research investigating how drug abuse impacts antibody responses in people living with HIV (PLWH), particularly among people who use substances and live with HIV (PWUSH). The...
- The National Institute on Drug Abuse awarded Boston Medical Center Corporation $1,593,298 under Project Grant R01DA066715 on July 1, 2026, to evaluate health impacts of municipal interventions addressing homelessness and opioid use disorder. The recipient will characterize longitudinal trends in overdose, health service use, and housing engagement among people experiencing homelessness from 2015 through 2024 across major policy actions; assess associations between homelessness programs and...
- The National Institute on Drug Abuse awarded Johns Hopkins University $198,164 on October 17, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct research examining barriers to medications for opioid use disorder (MOUD) treatment for individuals transitioning from correctional facilities to community settings. The research employs a complex systems approach combining quantitative and qualitative methods. Specific aims include examining the structure and function...
The National Institute on Drug Abuse awarded Boston Medical Center Corporation $870,407 on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support research on pre-release Medicaid effects on youth experiences related to substances (PRIME Years). The project addresses barriers to behavioral health service access for youth ages 16–25 following incarceration, a population with 36–84% prevalence of substance use history. The research examines Medicaid coverage suspension during incarceration and the critical gap in care post-release, with particular focus on why three in five eligible youth fail to reenroll. The study evaluates how Medicaid coverage and connection to behavioral health services affect youth outcomes during this high-risk transitional period, and addresses coverage of screenings and diagnostic services under the Consolidated Appropriations Act. Performance occurs in Roxbury, Massachusetts. The award runs through July 31, 2031, under the Project Grant assistance type. This is a parent award with no identified sub-recipients in the source material.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $870.4k | 8/26/26 |